Grufity logo
Grufity logo
OGN

OGN - Organon & Co. Stock Price, Fair Value and News

$13.540.00 (0.00%)
Delayed as of 28 Jul 2026, 03:50 pm ET

66/100

OGN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

66/100

OGN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

OGN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

OGN Price Action

Last 7 days

0.3%

Last 30 days

0.2%

Last 90 days

1.6%

Trailing 12 Months

32.5%

OGN RSI Chart

OGN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

OGN Valuation

Market Cap

3.6B

Price/Earnings (Trailing)

14.44

Price/Sales (Trailing)

0.58

EV/EBITDA

9.26

Price/Free Cashflow

5.2

OGN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

OGN Fundamentals

OGN Revenue

Revenue (TTM)

6.2B

Rev. Growth (Yr)

-3.5%

Rev. Growth (Qtr)

-3.12%

OGN Earnings

Earnings (TTM)

246.0M

Earnings Growth (Yr)

67.82%

Earnings Growth (Qtr)

171.22%

OGN Profitability

EBT Margin

8.71%

Return on Equity

27.24%

Return on Assets

1.89%

Free Cashflow Yield

19.22%

OGN Investor Care

Dividend Yield

0.59%

Dividend/Share (TTM)

0.08

Shares Dilution (1Y)

1.84%

Diluted EPS (TTM)

0.94

Revenue & Growth

How Organon & Co. generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
20266.2B---
20256.3B6.3B6.3B6.2B
20246.3B6.3B6.4B6.4B
20236.1B6.2B6.2B6.3B
20226.4B6.4B6.3B6.2B
20216.3B6.3B6.3B6.3B
20207.5B7.2B6.8B6.5B
2019---7.8B
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Organon & Co.

OGN
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive; Nuvaring, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
 CEO
 WEBSITEorganon.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers General
 EMPLOYEES10000

Organon & Co. Frequently Asked Questions

OGN is the stock ticker symbol of Organon & Co.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jul 27 2026, market cap of Organon & Co. is 3.55 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jul 27 2026, OGN's PE ratio (Price to Earnings) is 14.44 and Price to Sales (PS) ratio is 0.58. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OGN PE ratio will change depending on the future growth rate expectations of investors.